Advice on treatment of patient's admitted after acute myocardial infarctions

Description: Prototype of a decision support system developed by Cancer Research UK and BMJ Knowledge to demonstrate the incorporation of active (patient-specific) clinical decision support on the treatment of patients admitted to hospital following MI

Publet Introduction:


“The introduction of a national service framework for coronary heart disease in England and Wales was driven by evidence based medicine. Health service managers argued that clinicians were not reaping the proved benefits of interventions because of poor organisation. One good example of this is the use of thrombolysis in acute myocardial infarction.1 The delivery of thrombolytic agents during acute myocardial infarction is a well recognised and effective treatment, which has beneficial effects on mortality in both the short and the long term,2 and the earlier this treatment is given the greater the benefit. The focus on early administration of thrombolytic drugs led to the concept of “door to needle” time, with a target of 30 minutes, and a “call to needle” time of 60 minutes, incorporating the ambulance response time. But confusion still exists among many doctors about the absolute and relative contraindications to thrombolysis.”

BMJ Editorial, 2002, Dr. M W Savage

At the launch of Repertoire all applications are intended to have only exemplary value and should not be regarded as representing the current state of medical knowledge or practice.

Guideline Objectives
Target SettingEmergency Medicine
Target Users
  • Author
  • Release Date
Provenance7.No provenance has been assigned (default value)
Safety CaseNone developed

Clinical Evidence, 2000 (details)